Cellect Provides Corporate Update And Reports Second Quarter 2017 Financial Results
Published: Aug 21, 2017
TEL AVIV, Israel, Aug. 21, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 30, 2017.
"We are very pleased with our accomplishments in the first half of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. "As planned, 2017 is turning into a transformative year for Cellect Biotechnology. Cellect initiated its Phase I/II study on cancer patients undergoing matched related allogeneic HSCT transplantation and reported positive results in the first patient followed by the approval to recruit two more patients. Further, Cellect held a pre-IND meeting with the FDA that was very positive and Cellect is moving ahead with its plan to submit an IND".
Important progress was achieved with the company's IP portfolio – the major patent covering the composition of matter and use of the ApotainerTm was issued in US and Russia, the collaboration with Entegris was further consolidated by receiving a BIRDF non-equity grant, and the development of the Apotainer was accelerated.